LFB Biotechnologies to Collaborate with GTC Biotherapeutics on Coagulation Factor IX Program
FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that LFB Biotechnologies has agreed to include the recombinant human coagulation factor IX program in the existing collaboration between GTC and LFB. Under their collaboration, both the costs and profits of this program will be shared between GTC and LFB. LFB will fund the final $500,000 license fee payment due to ProGenetics, LLC in the second quarter of 2008. GTC retains exclusive marketing rights in North America for recombinant factor IX and LFB will receive exclusive marketing rights in Europe with co-exclusive marketing rights in Japan.